NightWare, Inc — SEC Form D Filing

NightWare, Inc filed an SEC Form D on March 6, 2026, reporting $250K raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
March 6, 2026
Amount reported
$250K
Round stage
Seed
Industry
Health Technology
Website
https://nightware.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Nightmare Disorder and associated nightmares can severely disrupt sleep and affect overall quality of life.

Solution

NightWare offers a prescription digital therapeutic system that helps reduce sleep disturbances related to Nightmare Disorder and PTSD-related nightmares.

Why now

There is a growing recognition and need for effective treatments for sleep disturbances linked to PTSD and Nightmare Disorder, particularly given their impact on mental health.

Verdict

Investors likely said yes to NightWare because of the emerging recognition of mental health solutions, particularly in the domain of digital therapeutics. They were implicitly betting on the growth of digital treatment modalities for specific challenges such as Nightmare Disorder and PTSD-related nightmares, which are increasingly relevant in today's mental health dialogue. This cleared because of a clear healthcare focus, not because the competitive landscape lacked similar solutions, which suggests limited upside from market saturation and potential reluctance among practitioners to adopt a new technology.

Source: SEC EDGAR Form D filing